# Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA

> **NCT07522996** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Transfusion-dependent Non-severe Aplastic Anemia

## Interventions

- **DRUG:** Enarodustat
- **DRUG:** Cyclosporin (CSA)

## Key facts

- **NCT ID:** NCT07522996
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07522996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07522996, "Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07522996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*